The Value of Stillness
Health Care: Drugs
Protalix BioTherapeutics Inc. (PLX: AMEX)
$5.08 0.04 | 0.79%
06/18/13 - 04:01 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -11.62M | -36.53M | -29.00M | -31.44M |
| Operating Gains/Losses | 240.00K | 344.00K | -617.00K | -218.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 243.00K | 3.89M | -6.86M | -1.22M |
| (Increase) Decrease in Inventories | -3.76M | 910.00K | -1.19M | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.98M | 6.15M | -1.03M | 7.78M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 1.28M | -3.00M | -4.56M | 64.61M |
| Other Non-Cash Items | 7.58M | 1.04M | 1.66M | 2.95M |
| Net Cash From Continuing Operations | 635.00K | -23.57M | -38.46M | 44.45M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 635.00K | -23.57M | -38.46M | 44.45M |
| Sale of Property, Plant & Equipment | 0.00 | 2.00K | 0.00 | 73.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -2.07M | -5.70M | -7.86M | -6.20M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | -52.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -2.29M | -5.87M | -7.99M | -6.17M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 26.56M | 20.93M | 501.00K | 293.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 26.56M | 20.93M | 501.00K | 293.00K |
| Effect of Exchange Rate Changes | 127.00K | -388.00K | 589.00K | 99.00K |
| Net Change in Cash & Cash Equivalents | 25.03M | -8.90M | -45.37M | 38.67M |
Portfolios with PLX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSharebuilder
- UserSUPRATRADE HOT STOCKS (BUY ...
- Usergilver Portfolio 1
- UserTop Biotech Short Squeeze P...
- UserEdwin Lee Portfolio 1
Latest PLX Headlines from TheStreet
- Protalix BioTherapeutics To Host Analyst Event In New York City 06.12.13 | 07:06 am
- Oversold Conditions For Protalix BioTherapeutics (PLX) 05.31.13 | 12:05 pm
- Protalix BioTherapeutics To Present At Three Upcoming Healthcare Conferences 05.29.13 | 07:05 am
- PLX July Options Begin Trading 05.20.13 | 04:05 pm
- Protalix BioTherapeutics To Present At The Oppenheimer 14th Annual Israeli Conference 05.08.13 | 07:05 am
- UPLYSO(TM) (alfataliglicerase) Approved In Mexico And Chile For The Treatment Of Gaucher Disease 04.29.13 | 07:04 am
- 5 Stocks Under $10 Set to Soar 04.04.13 | 01:04 pm
- Protalix BioTherapeutics Treats First Gaucher Patient In Phase I Study With PRX-112, An Orally-Administered Enzyme Treatment Of Gaucher Disease 04.02.13 | 07:04 am
- UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease 03.18.13 | 02:03 pm
- Protalix BioTherapeutics Receives Approval To Initiate Phase I Study In Gaucher Patients With PRX-112, An Orally-Administered Candidate For The Treatment Of Gaucher Disease 03.07.13 | 08:03 am
Press Releases for PLX
- Pfizer And Protalix BioTherapeutics Announce FDA Approval Of ELELYSO™ (taliglucerase Alfa) For The Treatment Of Gaucher Disease - Business Wire 05.01.12 | 06:05 pm
- FDA Extends Taliglucerase Alfa PDUFA Date To May 1, 2012 - PR Newswire 12.06.11 | 07:12 am
- Protalix Announces Successful European GMP Audit - PR Newswire 12.01.11 | 02:12 am
- Protalix's Acetylcholinesterase Demonstrates Potential Role In The Treatment Of Parkinson's Disease - PR Newswire 11.10.11 | 01:11 am
- Protalix BioTherapeutics To Present At Four Upcoming Conferences - PR Newswire 10.26.11 | 07:10 am
- Protalix BioTherapeutics To Present At The Jefferies 2011 Global Healthcare Conference - PR Newswire 09.21.11 | 07:09 am
- Protalix BioTherapeutics To Present At The UBS Global Life Sciences Conference - PR Newswire 09.13.11 | 08:09 am
- Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published In Blood, The Journal Of The American Society Of Hematology - PR Newswire 09.08.11 | 08:09 am
- Protalix BioTherapeutics Announces FDA Accepts For Review Complete Response Resubmission For Taliglucerase Alfa And Assigns PDUFA Date - PR Newswire 08.17.11 | 07:08 am
- Protalix Submits Reply To FDA Complete Response Letter For Taliglucerase Alfa And Reports Top-Line Results From The Company's Switchover Trial - PR Newswire 08.01.11 | 08:08 am
Partner Headlines for PLX
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem-BCRT Alliance Extended - Analyst Blog - NASDAQ 08.22.12 | 11:08 pm
- Pluristem Gets Green Light in India - Analyst Blog - NASDAQ 08.20.12 | 11:08 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- 6 Biotech Stocks With Huge Potential In May - Seeking Alpha 04.11.12 | 08:04 am
- Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising - Seeking Alpha 02.10.12 | 08:02 am
- Company News for December 7, 2011 - Corporate Summary - Zacks 12.07.11 | 09:12 am
- Protalix BioTherapeutics: FDA Delay Provides Attractive Entry Point - Seeking Alpha 12.07.11 | 09:12 am
- Morning Market Losers - Benzinga 12.06.11 | 09:12 am
